Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Arbutus Biopharma Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Arbutus Biopharma Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Androski Lindsay | President and CEO | 72,337 | Sep 23, 2026 | 2 |
| Nguyen Tuan | Chief Financial Officer | 159,963 | Sep 23, 2026 | 2 |
| Sawhney Roger | Director | 30,825 | Sep 23, 2026 | 2 |
| Beardsley Robert A | Director | 32,276 | Sep 23, 2026 | 2 |
| Hasija Anuj | Director | – | Mar 20, 2025 | 0 |
| Hastings David C | Chief Financial Officer | 249,824 | Feb 19, 2025 | 0 |
| Naftzger J. Christopher | General Counsel and CCO | 140,544 | Feb 19, 2025 | 0 |
| McElhaugh Michael J. | Interim President & CEO | 1,658,003 | Feb 19, 2025 | 0 |
| Sims Karen | Chief Medical Officer | 155,494 | Feb 19, 2025 | 0 |
| Manchester Keith S | Director | 46,069 | Aug 16, 2024 | 0 |
| Henriques Richard C Jr | Director | – | May 24, 2024 | 0 |
| Burgess Daniel D | Director | – | May 24, 2024 | 0 |
| Meyers James R | Director | – | May 24, 2024 | 0 |
| Torti Frank | Director | – | May 24, 2024 | 0 |
| Rewolinski Melissa | Director | – | May 24, 2024 | 0 |
| Sofia Michael J. | Chief Scientific Officer | 1,485,121 | Feb 5, 2024 | 0 |
| Howard Elizabeth | EVP, GC, Compliance | 86,024 | Feb 3, 2023 | 0 |
| Collier William H. | President and CEO | 216,500 | Feb 3, 2023 | 0 |
| Tran Tram | Director | – | May 26, 2022 | 0 |
| Picchio Gaston | Chief Development Officer | – | Jan 20, 2022 | 0 |
| Roivant Sciences Ltd. | 10% Owner | 38,847,462 | Oct 20, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Hastings David CChief Financial Officer | SSale | −22.2K | $3.28 | −$72.8K | −12.2%159.7K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Sims KarenChief Medical Officer | SSale | −19.3K | $3.28 | −$63.5K | −15.4%106.2K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | McElhaugh Michael J.Interim President & CEO | SSale | −23.8K | $3.28 | −$78.0K | −1.6%1.48M after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Naftzger J. ChristopherGeneral Counsel and CCO | SSale | −11.3K | $3.28 | −$37.2K | −11.6%86.2K after | 10b5-1 |
| Aug 16, 2024 (view filing) | Aug 14 | 2 days | Manchester Keith SDirector | SSale | −8.85K | $3.69 | −$32.6K | −16.1%46.1K after | |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Sims KarenChief Medical Officer | SSale | −4.36K | $2.31 | −$10.1K | −3.4%125.5K after | 10b5-1 |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Hastings David CChief Financial Officer | SSale | −9.59K | $2.31 | −$22.2K | −5.0%181.9K after | 10b5-1 |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Sofia Michael J.Chief Scientific Officer | SSale | −9.98K | $2.31 | −$23.1K | −0.7%1.49M after | 10b5-1 |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | McElhaugh Michael J.Interim President & CEO | SSale | −10.2K | $2.31 | −$23.5K | −0.7%1.50M after | 10b5-1 |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Sofia Michael J.Chief Scientific Officer | SSale | −200.0K | $5.09 | −$1.02M | −13.3%1.30M after |